- Home
- MPU vs MAIA Comparison
MPU vs MAIA Comparison
Compare MPU & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPU
- MAIA
- Stock Information
- Founded
- MPU 1989
- MAIA 2018
- Country
- MPU Singapore
- MAIA United States
- Employees
- MPU N/A
- MAIA N/A
- Industry
- MPU Transportation Services
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- MPU Consumer Discretionary
- MAIA Health Care
- Exchange
- MPU Nasdaq
- MAIA Nasdaq
- Market Cap
- MPU 51.4M
- MAIA 52.8M
- IPO Year
- MPU 1998
- MAIA 2022
- Fundamental
- Price
- MPU $1.42
- MAIA $2.00
- Analyst Decision
- MPU
- MAIA
- Analyst Count
- MPU 0
- MAIA 0
- Target Price
- MPU N/A
- MAIA N/A
- AVG Volume (30 Days)
- MPU 192.8K
- MAIA 346.7K
- Earning Date
- MPU 11-12-2024
- MAIA 11-12-2024
- Dividend Yield
- MPU N/A
- MAIA N/A
- EPS Growth
- MPU N/A
- MAIA N/A
- EPS
- MPU N/A
- MAIA N/A
- Revenue
- MPU $26,001,000.00
- MAIA N/A
- Revenue This Year
- MPU N/A
- MAIA N/A
- Revenue Next Year
- MPU N/A
- MAIA N/A
- P/E Ratio
- MPU N/A
- MAIA N/A
- Revenue Growth
- MPU 1444400.00
- MAIA N/A
- 52 Week Low
- MPU $0.77
- MAIA $1.17
- 52 Week High
- MPU $4.48
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- MPU 48.44
- MAIA 44.72
- Support Level
- MPU $1.15
- MAIA $1.97
- Resistance Level
- MPU $1.65
- MAIA $2.44
- Average True Range (ATR)
- MPU 0.16
- MAIA 0.20
- MACD
- MPU 0.01
- MAIA 0.00
- Stochastic Oscillator
- MPU 54.00
- MAIA 8.33
About MPU Mega Matrix Corp.
Mega Matrix Inc formerly Mega Matrix Inc is a holding company. It operates through its two subsidiaries Mega Metaverse Corp (Mega) and JetFleet Management Corp (JMC). The Company has two business segments which are comprised of : ETH staking business and The leasing of regional aircraft to foreign and domestic regional airlines. The majority of the company's revenue is earned through Leasing business segment.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.